HA

Hatch Bio Fund

VC
San Diego, CAWebsite
How to approach: cold outreach ok
Stage

Pre-Seed, Seed

Check Size

$500K – $3.0M

AUM

$50M

Portfolio

10+ companies

Team

4 partners

Investor activity
Last known investment: 2017Investments in last 12 months: 0

Investment Thesis

Focuses on early-stage biotech companies transforming health through innovative technology.

Meet the Team

LP

Lorenzo Pellegrini, Ph.D.

Managing Partner

life sciences
translational research
early-stage biotech
TM

Timothy M. Block, Ph.D.

Founder and Advisor

virology
hepatitis research
infectious disease therapeutics
MK

Michael Kresmer

Founding Partner

Biotech
Personalized Medicine
LP

Louis P. Kassa III, MPA

Founder and Advisor

biotechnology entrepreneurship
incubators
non-profit partnerships

Industry Focus

Invests In

Healthcare
Other
SaaS

Portfolio Companies (10)

2017

翰长

翰长生物医疗(深圳)有限公司

Healthcare

"Discovered via firm_website (high confidence)"

致力于通过人工智能、远程诊断和医疗技术,与全球专业健康服务者一起,共同提升人类健康水平。

翰长

翰长生物医疗(深圳)有限公司

Healthcare·Established

"Discovered via firm_website (high confidence)"

致力于通过人工智能、远程诊断和医疗技术,与全球专业健康服务者一起,共同提升人类健康水平。

Other

VI

Vittoria Biotherapeutics, Inc.

Biotechnology (Cell Therapy)·Clinical-stage (early, with 5-day manufacturing)

"Discovered via perplexity (medium confidence)"

Clinical-stage immunotherapy company developing novel CAR T cell therapies using the Senza5™ platform for solid tumors and autoimmune diseases, licensed from University of Pennsylvania.

LA

Latus Bio

Biotechnology (Gene Therapy)·Pre-clinical/early-stage

"Discovered via perplexity (medium confidence)"

Patient-centric gene therapy company developing proprietary AAV capsids screened in non-human primates for clinical administration, founded from Professor Beverly Davidson's lab.

MA

MasterSwitch Bio

Biotechnology (mRNA Therapeutics)·Pre-clinical/early-stage

"Discovered via perplexity (medium confidence)"

Joint spinout from University of Pittsburgh and University of Pennsylvania developing modified mRNA therapy targeting HNF4α for End Stage Liver Disease with cirrhosis; co-founded by Nobel laureate Dr. Drew Weissman.

LA

Ladder Bio (formerly ThirdLaw Molecular)

Biotechnology (Drug Discovery Platform)·Pre-clinical/early-stage

"Discovered via perplexity (medium confidence)"

Spinout from Temple University creating synthetic Spiroligomers™—orally available, cell-permeable peptide-like molecules—for selective protein binding across diverse targets.

HU

Hula Therapeutics

Immunotherapy / antigen discovery / engineered T cell or similar·Preclinical / early clinical discovery stage

"Discovered via openai_search (medium confidence)"

Immunotherapy spin-out from Children’s Hospital of Philadelphia; identifies tumor-essential, HLA-presented targets that are considered “undruggable” and engineers therapies to improve safety & efficacy in solid tumors.

HE

Helix

Genomic Testing
LA

Ladder Bio

Small molecule / peptide-mimetic / synthetic biologics·Preclinical / discovery stage

"Discovered via openai_search (medium confidence)"

Spin-out from Temple University; developed a synthetic, modular, fused-ring peptide-like platform (“Spiroligomers™”) that is cell-permeable & orally bioavailable to engage challenging protein targets; billions of library members.

GE

Genome Medical

Genomic Medicine

Browse More Investors

Frequently Asked Questions

See if Hatch Bio Fund is a match for your startup

Upload your pitch deck to see how well you match with Hatch Bio Fund and 200+ other VC firms.